Dacomitinib, another irreversible ErbB family blocker, significantly enhanced progression-free survival (PFS) compared to gefitinib in the first-line treatment of EGFR mutation-positive NSCLC patients [10]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.